AstraZeneca's Imfinzi shows sustained benefit in lung cancer study - Reuters

  1. AstraZeneca's Imfinzi shows sustained benefit in lung cancer study  Reuters
  2. Durvalumab plus chemotherapy, without tremelimumab, extends OS in small cell lung cancer  Healio
  3. Durable OS benefit boosts Imfinzi in lung cancer segment  The Pharma Letter
  4. AZ's immunotherapy combo fails in phase 3 lung cancer trial -  pharmaphorum
  5. AstraZeneca's Checkpoint Inhibitor Imfinzi Helps Overall Survival in Lung Cancer  PharmaLive
  6. View Full Coverage on Google News


Comments

Popular posts from this blog